Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of March 2026
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on regulatory notifications rather than financial performance data.
Material Changes
The filing discloses the submission of Exhibit 99.1, a "Notification regarding unquoted securities - ATH." No other material changes or comparative financial data versus prior periods are included in this specific report.
Guidance, Outlook, and Risks
The document does not contain management commentary, financial guidance, outlook, or specific risk factors. It serves primarily to incorporate the notification regarding unquoted securities into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the details of the "unquoted securities" referenced in Exhibit 99.1.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for broader context on capital structure.
- Confirm the company's status as a development stage enterprise and its current cash runway, as no financial metrics are provided here.